File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HER2 overexpression of breast cancers in Hong Kong: Prevalence and concordance between immunohistochemistry and in-situ hybridisation assays

TitleHER2 overexpression of breast cancers in Hong Kong: Prevalence and concordance between immunohistochemistry and in-situ hybridisation assays
Authors
KeywordsBreast neoplasms
Gene amplification
Immunohistochemistry
In situ hybridization, fluorescence
Receptor, epidermal growth factor
Issue Date2008
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hk
Citation
Hong Kong Medical Journal, 2008, v. 14 n. 2, p. 130-135 How to Cite?
AbstractObjectives: To evaluate the prevalence of human epidermal growth factor receptor 2 (HER2) gene overexpression in breast cancer patients encountered in Hong Kong and the concordance of HER2 findings from primary immunohistochemistry assays and confirmatory in-situ hybridisation assays. Design: Retrospective study. Setting: Department of Clinical Oncology in a public hospital in Hong Kong. Patients: All patient referrals between July 2006 and June 2007 with newly diagnosed invasive breast cancer (for prevalence evaluation), and all patients treated at our unit with confirmatory in-situ hybridisation tests performed within the study period (for concordance evaluation). Results: There were 272 consecutive breast cancer patients eligible for prevalence evaluation. The distribution for immunohistochemistry staining in 249 cases for scores 0, 1+, 2+, and 3+ were 99 (40%), 40 (16%), 58 (23%), and 52 (21%) respectively. In the remaining 23 patients, four and 19 breast cancers were unscored and reported by immunohistochemistry to be HER2-positive and -negative, respectively. The overall HER2 overexpression rate (3+ or reported as positive) was 21%. HER2 overexpression was associated with grade 3 histology (P<0.001) and negative hormonal receptor status (P<0.001). However, it was not associated with age (P=0.525), T-classification (P=0.740), N-classification (P=0.691), nor group stages (P=0.433). Of the 37 patients with confirmatory in-situ hybridisation tests performed, 10 (71%) of 14 with immunohistochemistry staining of 3+ and 1 (4%) of 23 with immunohistochemistry staining of 2+ were found to have HER2 gene amplification. Conclusions: More than 25% of HER2 overexpression identified by immunohistochemistry assays in this Hong Kong cohort could not be verified by confirmatory in-situ hybridisation assays. Compliance with the latest guidelines for HER2 testing should improve the future accuracy and concordance.
Persistent Identifierhttp://hdl.handle.net/10722/57149
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279
References

 

DC FieldValueLanguage
dc.contributor.authorYau, TKen_HK
dc.contributor.authorSze, Hen_HK
dc.contributor.authorSoong, ISen_HK
dc.contributor.authorHioe, Fen_HK
dc.contributor.authorKhoo, USen_HK
dc.contributor.authorLee, AWMen_HK
dc.date.accessioned2010-04-12T01:27:22Z-
dc.date.available2010-04-12T01:27:22Z-
dc.date.issued2008en_HK
dc.identifier.citationHong Kong Medical Journal, 2008, v. 14 n. 2, p. 130-135en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/57149-
dc.description.abstractObjectives: To evaluate the prevalence of human epidermal growth factor receptor 2 (HER2) gene overexpression in breast cancer patients encountered in Hong Kong and the concordance of HER2 findings from primary immunohistochemistry assays and confirmatory in-situ hybridisation assays. Design: Retrospective study. Setting: Department of Clinical Oncology in a public hospital in Hong Kong. Patients: All patient referrals between July 2006 and June 2007 with newly diagnosed invasive breast cancer (for prevalence evaluation), and all patients treated at our unit with confirmatory in-situ hybridisation tests performed within the study period (for concordance evaluation). Results: There were 272 consecutive breast cancer patients eligible for prevalence evaluation. The distribution for immunohistochemistry staining in 249 cases for scores 0, 1+, 2+, and 3+ were 99 (40%), 40 (16%), 58 (23%), and 52 (21%) respectively. In the remaining 23 patients, four and 19 breast cancers were unscored and reported by immunohistochemistry to be HER2-positive and -negative, respectively. The overall HER2 overexpression rate (3+ or reported as positive) was 21%. HER2 overexpression was associated with grade 3 histology (P<0.001) and negative hormonal receptor status (P<0.001). However, it was not associated with age (P=0.525), T-classification (P=0.740), N-classification (P=0.691), nor group stages (P=0.433). Of the 37 patients with confirmatory in-situ hybridisation tests performed, 10 (71%) of 14 with immunohistochemistry staining of 3+ and 1 (4%) of 23 with immunohistochemistry staining of 2+ were found to have HER2 gene amplification. Conclusions: More than 25% of HER2 overexpression identified by immunohistochemistry assays in this Hong Kong cohort could not be verified by confirmatory in-situ hybridisation assays. Compliance with the latest guidelines for HER2 testing should improve the future accuracy and concordance.en_HK
dc.languageengen_HK
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org.hken_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Medical Association.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectBreast neoplasmsen_HK
dc.subjectGene amplificationen_HK
dc.subjectImmunohistochemistryen_HK
dc.subjectIn situ hybridization, fluorescenceen_HK
dc.subjectReceptor, epidermal growth factoren_HK
dc.subject.meshBreast Neoplasms - epidemiology - genetics - pathologyen_HK
dc.subject.meshCarcinoma, Ductal - epidemiology - genetics - pathologyen_HK
dc.subject.meshCarcinoma, Lobular - epidemiology - genetics - pathologyen_HK
dc.subject.meshImmunohistochemistryen_HK
dc.subject.meshIn Situ Hybridization - methodsen_HK
dc.titleHER2 overexpression of breast cancers in Hong Kong: Prevalence and concordance between immunohistochemistry and in-situ hybridisation assaysen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=14&issue=2&spage=130&epage=135&date=2008&atitle=HER2+overexpression+of+breast+cancers+in+Hong+Kong:+prevalence+and+concordance+between+immunohistochemistry+and+in-situ+hybridisation+assaysen_HK
dc.identifier.emailSze, H: henrysze@graduate.hku.hken_HK
dc.identifier.emailKhoo, US: uskhoo@hku.hken_HK
dc.identifier.authoritySze, H=rp01697en_HK
dc.identifier.authorityKhoo, US=rp00362en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid18382020-
dc.identifier.scopuseid_2-s2.0-47249105596en_HK
dc.identifier.hkuros145274-
dc.identifier.hkuros266653-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-47249105596&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue2en_HK
dc.identifier.spage130en_HK
dc.identifier.epage135en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridYau, TK=7006540678en_HK
dc.identifier.scopusauthoridSze, H=23490726900en_HK
dc.identifier.scopusauthoridSoong, IS=9239786900en_HK
dc.identifier.scopusauthoridHioe, F=6701855177en_HK
dc.identifier.scopusauthoridKhoo, US=7004195799en_HK
dc.identifier.scopusauthoridLee, AWM=17035384900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats